Our Director of R&D, Rachel Liberatore, PhD, participated as a panelist in NIH Summit on “Anti-SARS-CoV-2 Antibodies for Treatment and Prevention of COVID-19: Lessons Learned and Remaining Questions”.
One of this summit’s goal is to summarize current knowledge and lessons learned on clinically relevant anti-SARS-CoV-2 antibodies for the treatment and/or prevention of COVID-19. Identify key unanswered scientific questions to catalyze clinical development and implementation is another relevant purpose.
The publicly broadcasted Summit began with opening remarks from NIH Director Dr. Francis S. Collins, Acting FDA Commissioner Dr. Janet Woodcock, and NIAID Director Dr. Anthony S. Fauci.
We also assisted at presentations on the current state of the science as well as three discussion sessions addressing the design, development and real world use of anti-SARS-CoV-2 antibodies.